Barry Canton Sells 219,088 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Stock

Ginkgo Bioworks Holdings, Inc. (NYSE:DNAGet Rating) major shareholder Barry Canton sold 219,088 shares of the stock in a transaction dated Wednesday, November 16th. The stock was sold at an average price of $2.42, for a total transaction of $530,192.96. Following the transaction, the insider now owns 20,943,633 shares in the company, valued at $50,683,591.86. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Barry Canton also recently made the following trade(s):

  • On Monday, November 14th, Barry Canton sold 208,632 shares of Ginkgo Bioworks stock. The stock was sold at an average price of $2.72, for a total transaction of $567,479.04.
  • On Thursday, November 10th, Barry Canton sold 186,028 shares of Ginkgo Bioworks stock. The stock was sold at an average price of $2.46, for a total transaction of $457,628.88.
  • On Tuesday, November 8th, Barry Canton sold 193,616 shares of Ginkgo Bioworks stock. The stock was sold at an average price of $2.46, for a total transaction of $476,295.36.
  • On Friday, November 4th, Barry Canton sold 204,906 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $2.51, for a total transaction of $514,314.06.
  • On Tuesday, November 1st, Barry Canton sold 196,308 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $2.77, for a total transaction of $543,773.16.
  • On Thursday, October 27th, Barry Canton sold 204,478 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $2.71, for a total transaction of $554,135.38.
  • On Monday, October 24th, Barry Canton sold 206,503 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $2.48, for a total transaction of $512,127.44.
  • On Thursday, October 20th, Barry Canton sold 196,721 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $2.47, for a total transaction of $485,900.87.
  • On Tuesday, October 18th, Barry Canton sold 198,051 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $2.64, for a total transaction of $522,854.64.
  • On Friday, October 14th, Barry Canton sold 215,948 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $2.62, for a total transaction of $565,783.76.

Ginkgo Bioworks Stock Performance

Shares of DNA stock opened at $2.19 on Friday. Ginkgo Bioworks Holdings, Inc. has a 12 month low of $1.96 and a 12 month high of $13.74. The company has a debt-to-equity ratio of 0.04, a current ratio of 11.71 and a quick ratio of 11.78. The firm has a market capitalization of $3.91 billion, a P/E ratio of -0.96 and a beta of 0.89. The company’s fifty day moving average price is $2.80 and its two-hundred day moving average price is $2.84.

Wall Street Analysts Forecast Growth

DNA has been the topic of several research reports. Morgan Stanley began coverage on shares of Ginkgo Bioworks in a report on Tuesday, October 4th. They issued an “equal weight” rating and a $5.00 price target on the stock. BTIG Research dropped their price target on shares of Ginkgo Bioworks to $4.00 in a research note on Thursday. Finally, Raymond James cut their price objective on shares of Ginkgo Bioworks from $14.50 to $10.50 and set an “outperform” rating on the stock in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $6.55.

Institutional Investors Weigh In On Ginkgo Bioworks

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Almanack Investment Partners LLC. increased its position in shares of Ginkgo Bioworks by 22.3% in the 2nd quarter. Almanack Investment Partners LLC. now owns 17,850 shares of the company’s stock worth $42,000 after purchasing an additional 3,250 shares during the last quarter. 180 Wealth Advisors LLC increased its position in shares of Ginkgo Bioworks by 14.2% in the 2nd quarter. 180 Wealth Advisors LLC now owns 30,094 shares of the company’s stock worth $72,000 after purchasing an additional 3,733 shares during the last quarter. Treasurer of the State of North Carolina increased its position in shares of Ginkgo Bioworks by 1.3% in the 3rd quarter. Treasurer of the State of North Carolina now owns 351,677 shares of the company’s stock worth $1,097,000 after purchasing an additional 4,540 shares during the last quarter. Formidable Asset Management LLC increased its position in shares of Ginkgo Bioworks by 32.1% in the 2nd quarter. Formidable Asset Management LLC now owns 20,332 shares of the company’s stock worth $64,000 after purchasing an additional 4,946 shares during the last quarter. Finally, Bradley Foster & Sargent Inc. CT increased its position in shares of Ginkgo Bioworks by 7.3% in the 2nd quarter. Bradley Foster & Sargent Inc. CT now owns 74,390 shares of the company’s stock worth $177,000 after purchasing an additional 5,035 shares during the last quarter. Institutional investors own 53.37% of the company’s stock.

Ginkgo Bioworks Company Profile

(Get Rating)

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.

Recommended Stories

Insider Buying and Selling by Quarter for Ginkgo Bioworks (NYSE:DNA)

Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.